# | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
---|---|---|---|---|---|---|---|---|---|
1. | ALA4805273 | B | Inhibition of recombinant human STK19 at 10 uM using HA-tagged GTP-preloaded NRAS as substrate incubated for 0-40 mins and measured by ADP-Glo assay relative to control | Homo sapiens | 46 | single protein format | Patent Bioactivity Data | ||
2. | ALA4805274 | B | Inhibition of recombinant human STK19 using HA-tagged GTP-preloaded NRAS as substrate incubated for 0-40 mins and measured by ADP-Glo assay | Homo sapiens | 17 | single protein format | Patent Bioactivity Data | ||
3. | ALA4805275 | B | Inhibition of recombinant human STK19 assessed as NRAS phosphorylation in presence of 10 uM ATP | Homo sapiens | 1 | single protein format | Patent Bioactivity Data | ||
4. | ALA4805276 | B | Inhibition of recombinant human STK19 assessed as NRAS phosphorylation in presence of 30 uM ATP | Homo sapiens | 1 | single protein format | Patent Bioactivity Data | ||
5. | ALA4805277 | B | Inhibition of recombinant human STK19 assessed as NRAS phosphorylation in presence of 100 uM ATP | Homo sapiens | 1 | single protein format | Patent Bioactivity Data | ||
6. | ALA4805278 | B | Inhibition of recombinant human STK19 assessed as NRAS phosphorylation in presence of 300 uM ATP | Homo sapiens | 1 | single protein format | Patent Bioactivity Data | ||
7. | ALA4805279 | B | Inhibition of G9a (unknown origin) by methyltransferase assay | Homo sapiens | 1 | single protein format | Patent Bioactivity Data | ||
8. | ALA4805280 | B | Inhibition of recombinant human STK19 assessed as NRAS phosphorylation at 1-3 uM relative to control | Homo sapiens | 1 | single protein format | Patent Bioactivity Data | ||
9. | ALA4805281 | B | Binding affinity to recombinant human STK19 assessed as change in melting temperature | Homo sapiens | 1 | single protein format | Patent Bioactivity Data | ||
10. | ALA4805282 | B | Inhibition of wild-type STK19 (unknown origin) by biochemical assay | Homo sapiens | 1 | single protein format | Patent Bioactivity Data | ||
11. | ALA4805283 | B | Inhibition of STK19 V134Y mutant (unknown origin) by biochemical assay | Homo sapiens | 1 | single protein format | Patent Bioactivity Data | ||
12. | ALA4805284 | B | Inhibition of STK19 L139F mutant (unknown origin) by biochemical assay | Homo sapiens | 1 | single protein format | Patent Bioactivity Data | ||
13. | ALA4805285 | B | Inhibition of STK19 D89N mutant (unknown origin) by biochemical assay | Homo sapiens | 1 | single protein format | Patent Bioactivity Data | ||
14. | ALA4805286 | B | Inhibition of wild-type STK19 in human primary melanocytes at 0.1-3 uM relative to control | Homo sapiens | 1 | cell-based format | Patent Bioactivity Data | ||
15. | ALA4805287 | B | Inhibition of STK19 D89N mutant in human primary melanocytes at 0.1-3 uM relative to control | Homo sapiens | 1 | cell-based format | Patent Bioactivity Data | ||
16. | ALA4805288 | T | Toxicity in C57BL/6J mouse assessed as effect on animal body weight at 25 mg/kg, administered twice daily for 20 days | Mus musculus | 1 | organism-based format | Patent Bioactivity Data | ||
17. | ALA4805289 | T | Toxicity in C57BL/6J mouse assessed as effect on alanine aminotransferase level at 25 mg/kg, administered twice daily for 20 days | Mus musculus | 1 | organism-based format | Patent Bioactivity Data | ||
18. | ALA4805290 | T | Toxicity in C57BL/6J mouse assessed as effect on aspartate aminotransferase level at 25 mg/kg, administered twice daily for 20 days | Mus musculus | 1 | organism-based format | Patent Bioactivity Data | ||
19. | ALA4805291 | T | Toxicity in C57BL/6J mouse assessed as effect on total bilirubin level at 25 mg/kg, administered twice daily for 20 days | Mus musculus | 1 | organism-based format | Patent Bioactivity Data | ||
20. | ALA4805292 | T | Toxicity in C57BL/6J mouse assessed as effect on alkaline phosphatase level at 25 mg/kg, administered twice daily for 20 days | Mus musculus | 1 | organism-based format | Patent Bioactivity Data |